Protara Therapeutics (TARA) Debt to Equity (2013 - 2020)

Protara Therapeutics (TARA) recorded quarterly Debt to Equity of $0.0 in Q3 2020, down 87.79% quarter-over-quarter from $0.02 in Q2 2020.

Protara Therapeutics (TARA) Debt to Equity (2013 - 2020) Analysis & Trends

Protara Therapeutics' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.0 for Q3 2020.

In Q3 2020, Debt to Equity changed N/A year-over-year to $0.0; the TTM figure through Sep 2020 stood at $0.0 (changed N/A YoY), while the FY2013 annual figure was -$0.01, changed N/A from the prior year.
Debt to Equity was $0.0 for Q3 2020 at Protara Therapeutics, down from $0.02 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.02 in Q1 2020 to a low of $0.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Protara Therapeutics	216.35 Mn	216.35 Mn	-	-

Download Data